Anti-Angiogenesis Strategies in Cancer Therapies
- 1st Edition - December 1, 2016
- Latest edition
- Authors: Shaker Mousa, Paul Davis
- Language: English
- Paperback ISBN:9 7 8 - 0 - 1 2 - 8 0 2 5 7 6 - 5
- eBook ISBN:9 7 8 - 0 - 1 2 - 8 0 2 6 7 3 - 1
Anti-angiogenesis Strategies in Cancer Therapeutics provides a detailed look at the current status and future directions in the discovery and development of novel anti-angi… Read more
Anti-angiogenesis Strategies in Cancer Therapeutics provides a detailed look at the current status and future directions in the discovery and development of novel anti-angiogenesis strategies in oncology. This book highlights the different mechanisms involved in the modulation of angiogenesis, including inflammation, thrombosis, and microRNA, and shows how nanotechnology can further enhance the potential of existing and new anti-angiogenesis approaches.
Written for industry scientists, researchers, oncologists, hematologists, and professors and students in the field, this comprehensive book covers all aspects of anti-angiogenesis strategies and their differences.
- Covers important preclinical models and clinical trials in the discovery and development of novel anti-angiogenesis agents
- Reviews FDA-approved anti-angiogenesis agents
- Illustrates the value of nanotechnology in improving the utility of anti-angiogenesis agents
- Offers insight into the development of novel anti-angiogenesis agents and future direction in this area
Pharmaceutical scientists and researchers in pharmaceutical and biotechnology companies, oncologists, hematologists, graduate and post-graduate students in these areas and academic faculty
- List of contributors
- Introduction
- Chapter 1: Angiogenesis and Anti-Angiogenesis Strategies in Cancer
- Abstract
- Process of Angiogenesis
- Angiogenesis in Cancer
- Strategies
- Current Examples of Cancer Treatment Agents that Block Angiogenesis
- Side Effects of Angiogenesis Inhibitors
- Angiogenesis and Angiogenesis Inhibitors: Potential Anti-cancer Therapeutic Efficacy
- Additional Anti-angiogenesis Strategies in Cancers
- Anti-angiogenesis Therapy in Hematologic Cancer: Multiple Myeloma
- Anti-coagulants and Angiogenesis
- Possible Mechanisms of Acquired Resistance to Anti-angiogenic Drugs
- Standard Chemotherapy Versus Angiogenesis Inhibitors
- Anti-angiogenesis Agents and Thrombosis
- Diagnostic Imaging of Angiogenesis
- microRNA and Angiogenesis Modulation
- Chapter 2: Models for Assessing Anti-Angiogenesis Agents: Appraisal of Current Techniques
- Abstract
- In Vivo Assays
- In Vitro Assays
- Three-Dimensional Matrix Array Ultrasound Molecular Imaging
- Coculture of Human Cancer Cells with Human Microvascular Endothelial Cells
- Discussion
- Conclusions
- Chapter 3: Anti-Angiogenesis in Multiple Myeloma
- Abstract
- Angiogenesis in Multiple Myeloma
- Thalidomide and its Analogs
- Bortezomib
- Tyrosine Kinase Inhibitors (TKIs)
- Zoledronic Acid
- Conclusions
- Acknowledgments
- Chapter 4: Interface between Thrombosis, Inflammation, and Angiogenesis in Cancer Progression
- Abstract
- Cancer-associated Thrombosis
- TF-VIIa-PAR2 Signaling Regulates Angiogenesis
- TF-VIIa-PAR2 Signaling Regulates Inflammation
- Role of TF-VIIa in Cellular Signaling
- Conclusions
- Chapter 5: microRNAs and Angiogenesis
- Abstract
- Introduction
- Specific miRNAs and Angiogenesis
- Chapter 6: Naturally Occurring Angiogenesis Inhibitors
- Abstract
- Introduction
- Nutraceutical-Derived Polyphenol Angiogenesis Inhibitors
- Marine Nonglycosaminoglycan Sulfated Glycans
- Natural Lipid Products
- Chapter 7: Integrin Antagonists and Angiogenesis
- Abstract
- Integrins
- Integrins and Signaling
- Cell Surface Membrane Integrins as Potential Drug Discovery Targets
- Diagnostics
- Integrin–Hormone Crosstalk: Integrin Receptor-Mediated Actions of Thyroid Hormone
- Conclusions
- Chapter 8: Tyrosine Kinase Inhibitors and Angiogenesis
- Abstract
- Introduction
- Examples of Specific TKIs
- Impact of Angiogenesis-Active TKIs on Clinical Outcomes
- Conclusions
- Chapter 9: Tetraiodothyroacetic Acid at Integrin αvβ3: A Model of Pharmaceutical Anti-Angiogenesis
- Abstract
- Introduction
- Thyroid Hormone is a Proangiogenic Agent and Tetrac is an Anti-angiogenic Agent
- Tetrac, NDAT, and Angiogenesis-relevant Gene Expression and microRNA Expression
- Tetrac, NDAT, and Actions of Vascular Growth Factors
- Tetrac and NDAT Actions on Endothelial Cells
- Anti-angiogenesis of NDAT in the Retina
- Anti-angiogenesis of NDAT in Human Tumor Xenografts
- Action of NDAT on Mechanisms of Vascular Sprouting
- Pharmacodynamics of NDAT
- Side Effect Profile of NDAT
- Conclusions
- Chapter 10: Anti-Angiogenesis Therapy and its Combination with Chemotherapy: Impact on Primary Tumor and its Metastasis
- Abstract
- Introduction
- Biomarkers of Angiogenesis
- Impact of Angiogenesis on Tumor Growth and Metastasis
- Current Anti-angiogenic Therapies
- Problems Encountered with Anti-angiogenic Therapy
- Distinctive Features of Tumor-Related Angiogenesis
- Novel Anti-angiogenesis Strategies
- Anti-angiogenesis and Nanotargeting
- Conclusions
- Chapter 11: Application of Nanotechnology to Target Tumor Angiogenesis in Cancer Therapeutics
- Abstract
- Introduction
- Angiogenesis
- Integrins
- Gene Therapy Delivery with Nanoparticles
- Conclusions
- Chapter 12: New Directions in Anti-Angiogenesis Research
- Abstract
- Introduction
- Projections
- Conclusions
- Acknowledgment
- Index
- Edition: 1
- Latest edition
- Published: December 1, 2016
- Language: English
SM
Shaker Mousa
Dr. Mousa came to Albany College of Pharmacy and Health Sciences in 2002 following a career of more than 17 years as a principal research scientist at DuPont Pharmaceuticals Co. Among Dr. Mousa's professional accomplishments are his contributions to many patents – he holds more than 250 U.S. and international patents – and to the discovery and development of novel anti-platelet, anti-thrombotic therapies, non-invasive myocardial perfusion and thrombus imaging agents. Dr. Mousa serves on the editorial boards and as a reviewer for a number of scientific and medical journals, including Journal of Pharmaceutical Sciences, Frontiers in Molecular Neuroscience, Clinical and Applied Thrombosis/Hemostasis, Applied Microbiology and Biotechnology, and PLoS Computational Biology.
Affiliations and expertise
Vice Provost for Research and Professor of Pharmacology, Albany College of Pharmacy and Health Sciences, Rensselaer, NY, USAPD
Paul Davis
Dr. Davis directs a group of scientists who have defined molecular mechanisms for many non-genomic, plasma membrane-initiated actions of thyroid hormone, including actions on plasma membrane ion transporters, intracellular protein trafficking, phosphorylation of nuclear hormone receptors and of p53 and on transcription of specific genes. He has 5 patents issued and 25 US and international applications pending. Dr. Davis is a US Faculty Head in Endocrinology of the Faculty of 1000 Medicine and a member of the Endocrine Society, American Thyroid Association, American Society of Biochemistry and Molecular Biology, American Diabetes Association, American Association for Cancer Research and a Fellow of the American College of Physicians.
Affiliations and expertise
Professor of Pharmacy, The Pharmaceutical Research Institute, Albany College of Pharmacy and Health Sciences, Rensselaer, NY, USARead Anti-Angiogenesis Strategies in Cancer Therapies on ScienceDirect